A Mechanism Study to Investigate the Difference in Efficacy of Neoadjuvant PD-1 Blockade Combined With Chemotherapy in the Treatment of IIA-IIIB Stage Lung Squamous Cell Carcinoma
Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY
To explore mechanisms of immunotherapy resistance and relation to changes in the TME before and after PD-1 blockade combined with chemotherapy
Eligibility
Participation Requirements
Sex: All
Minimum Age: 40
Maximum Age: 80
Healthy Volunteers: f
View:
• aged 40 to 80 years;
• had histologically confirmed LUSC with operable locally advanced stage
• no prior anti-tumor therapy; received neoadjuvant immunotherapy consisting of three cycles of anti-PD-1 ICB plus nab-paclitaxel and carboplatin
• pre-treatment tissues
Locations
Other Locations
China
Hongtao Duan
RECRUITING
Xi’an
Time Frame
Start Date: 2024-01-24
Estimated Completion Date: 2025-05-16
Participants
Target number of participants: 40
Treatments
MPR(major pathological response)
defned as having no more than 10% residual viable tumor cells by routine hematoxylin and eosin (H\&E) staining after therapy
non-MPR
defned as having more than 10% residual viable tumor cells by routine hematoxylin and eosin (H\&E) staining after therapy
Related Therapeutic Areas
Sponsors
Leads: Tang-Du Hospital